

Accepted Manuscript

Title: Brain accumulation of the EML4-ALK inhibitor ceritinib is restricted by P-glycoprotein (P-GP/ABCB1) and breast cancer resistance protein (BCRP/ABCG2)

Author: Anita Kort Rolf W. Sparidans Els Wagenaar Jos H. Beijnen Alfred H. Schinkel



PII: S1043-6618(15)00207-8
DOI: <http://dx.doi.org/doi:10.1016/j.phrs.2015.09.003>
Reference: YPHRS 2925

To appear in: *Pharmacological Research*

Received date: 21-7-2015
Revised date: 4-9-2015
Accepted date: 4-9-2015

Please cite this article as: Kort Anita, Sparidans Rolf W, Wagenaar Els, Beijnen Jos H, Schinkel Alfred H. Brain accumulation of the EML4-ALK inhibitor ceritinib is restricted by P-glycoprotein (P-GP/ABCB1) and breast cancer resistance protein (BCRP/ABCG2). *Pharmacological Research* <http://dx.doi.org/10.1016/j.phrs.2015.09.003>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Brain accumulation of the EML4-ALK inhibitor ceritinib is restricted by P-glycoprotein (P-GP/ABCB1) and breast cancer resistance protein (BCRP/ABCG2)

Anita Kort^{a,c}, Rolf W. Sparidans^b, Els Wagenaar^a, Jos H. Beijnen^{b,c,d} and Alfred H. Schinkel^{a*}

Authors' Affiliations:

^a Division of Molecular Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands. a.kort@nki.nl

^b Division of Pharmacoepidemiology & Clinical Pharmacology, Department of Pharmaceutical Sciences, Faculty of Science, Utrecht University, Universiteitsweg 99, 3584 CG Utrecht, the Netherlands. r.w.sparidans@uu.nl

^c Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute – Antoni van Leeuwenhoek, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands. j.beijnen@nki.nl

^d Department of Clinical Pharmacology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands.

***Corresponding author:**

Dr. Alfred H. Schinkel

The Netherlands Cancer Institute, Division of Molecular Oncology, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands

E-mail: a.schinkel@nki.nl

Phone: +31 20 512 2046

Fax: +31 20 669 1383

Graphical abstract

Download English Version:

<https://daneshyari.com/en/article/5843665>

Download Persian Version:

<https://daneshyari.com/article/5843665>

[Daneshyari.com](https://daneshyari.com)